The number of people diagnosed with asbestos caused diseases in the U.S. continues to increase. Experts believe 60,000 mesothelioma deaths will occur between 2010 and 2030.

Work related injuries harm up to 14 million people annually, with harms including traumatic brain injuries, spinal injuries, amputations, burns, and electrocutions. Around 20,000 to 60,000 workers die each year from accidents, toxins, and violence at their jobs.

Millions of consumers and workers are injured each year because of defective products. Defects can occur when a product is designed poorly, when a product is manufactured in a manner that differs from the intended design, or when the product does not contain proper warnings or instructions. Defects can occur in automobiles, pharmaceuticals, medical devices, construction equipment, toys, and other goods.

Between 1.5 and 2 million elderly reside in nursing home facilities, with studies revealing that 44% have suffered some form of abuse. Many believe the actual number of residents suffering abuse is much higher. Neglect and abuse may result in serious emotional, physical, and financial harm

Paul & Hanley’s legal team has produced some of the most notable verdicts and highest settlements in the United States. Over 500 of our clients have each obtained in excess of 1 million dollars. Over 250 have recovered multi-million dollar recoveries.

Screening Trial: Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

No phase specified

Age:  50 to 85

Protocol ID:  NCT00188890

Trial Description

Occupational exposure to asbestos is known increase the risk of developing cancer of the lungs (bronchogenic carcinoma) or of the pleura (mesothelioma).  Symptoms are subtle and non-specific, diagnosis is often late and the prognosis consequently is dismal.  Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. In the last decade, low-dose computed tomography (LDCT) has been successfully developed and validated for the early diagnosis of lung cancer in high-risk smokers.  Malignant mesothelioma might, in an early stage, resemble a benign pleural plaque, which is a common finding after asbestos exposure.  We target to develop low-dose CT as a tool to serially image the pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and, as such, identify the presence of mesothelioma early, before symptoms occur.

Eligibility Criteria

Inclusion Criteria:

prior asbestos exposure at least twenty years ago and/or documented pleural plaques (chest x-ray evidence)

Resident of Ontario, Canada

Exclusion Criteria:

prior cancer (except non-melanotic skin cancer)

Trial Lead Organizations/Sponsors

Toronto Western Hospital

Demetris Patsios, MD Principal Investigator

Michael R. Johnston Principal Investigator

Demetris Patsios, MD Ph: Tel: (416) 603-5800 Ext.2583
Email: demetris.patsios@uhn.on.ca

Brenda O'Sullivan Ph: 416-340-4800 Ext.5686
Email: Brenda.O'Sullivan@uhn.on.ca

Trial Sites

Canada

Ontario

Toronto

Princess Margaret Hospital

Demetris Patsios, MD Ph: Tel: (416) 603-5800 Ext.2583
Email: demetris.patsios@uhn.on.ca 1

Brenda O'Sullivan, MD Ph: 416-340-4800 Ext.5686
Email: brenda.o'sullivan@uhn.on.ca 2

Link to the current ClinicalTrials.gov record. 3
NLM Identifer NCT00188890
Information obtained from ClinicalTrials.gov on April 05, 2010

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.